The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo

The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo

Background: Fascin1 is the key actin-bundling protein involved in cancer invasion and metastasis whose expression is associated with bad prognosis in tumor from different origins. Methods: In the present study, virtual screening (VS) was performed for the search of Fascin1 inhibitors and RAL, an FDA...

Full description

Bibliographic Details
Main Authors: Begoña Alburquerque-González, Ángel Bernabé-García, Manuel Bernabé-García, Javier Ruiz-Sanz, Fernando Feliciano López-Calderón, Leonardo Gonnelli, Lucia Banci, Jorge Peña-García, Irene Luque, Francisco José Nicolás, María Luisa Cayuela-Fuentes, Enrico Luchinat, Horacio Pérez-Sánchez, Silvia Montoro-García, Pablo Conesa-Zamora
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
Fascin1
raltegravir
migrastatin
invasion
migration
zebrafish xenograft
Online Access:https://www.mdpi.com/2072-6694/13/4/861

Internet

https://www.mdpi.com/2072-6694/13/4/861

Similar Items